Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : J.P. Morgan
Deal Size : $300.0 million
Deal Type : Public Offering
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
Details : The net proceeds will fund the development of VT-001 (atacicept), a BAFF/APRIL inhibitor currently under evaluation for treating patients with IgA nephropathy.
Brand Name : VT-001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 29, 2024
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : J.P. Morgan
Deal Size : $300.0 million
Deal Type : Public Offering
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vera Therapeutics Announces Expanded Atacicept Program in Autoimmune Kidney Diseases
Details : VT-001 (atacicept) is a BLyS/APRIL inhibitor protein drug candidate, which is currently being evaluated for the treatment of patients with IgA nephropathy.
Brand Name : VT-001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 02, 2024
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vera Therapeutics Completes Enrollment in Phase 3 ORIGIN 3 Trial of Atacicept for IgAN
Details : VT-001 (atacicept) is a BLyS/APRIL inhibitor protein drug candidate, which is currently being evaluated for the treatment of patients with IgA nephropathy.
Brand Name : VT-001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 12, 2024
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vera's Atacicept gets FDA Breakthrough Therapy for IgA nephropathy
Details : VT-001 (atacicept) has been granted breakthrough therapy designation for the treatment of IgAN. It is currently being evaluated in late-stage clinical trials.
Brand Name : VT-001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 28, 2024
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : J.P. Morgan
Deal Size : $287.5 million
Deal Type : Public Offering
Vera Therapeutics Closes Upsized Public Offering Of Class A Common Stock
Details : The net proceeds will fund Phase 3 clinical trial of VT-001 (atacicept), a fusion protein given subcutaneously, for IgAN, along with regulatory submissions and potential commercial launch preparation.
Brand Name : VT-001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 01, 2024
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : J.P. Morgan
Deal Size : $287.5 million
Deal Type : Public Offering
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : J.P. Morgan
Deal Size : $250.0 million
Deal Type : Public Offering
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
Details : Proceeds will fund VT-001 (atacicept) development, targeting autoantibodies in autoimmune diseases like IgAN (Berger's disease) and lupus nephritis.
Brand Name : VT-001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 29, 2024
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : J.P. Morgan
Deal Size : $250.0 million
Deal Type : Public Offering
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VT-001 (atacicept) is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor that binds to the cytokines B lymphocyte stimulator and a proliferation-in...
Brand Name : VT-001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 07, 2023
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : J.P. Morgan
Deal Size : $115.0 million
Deal Type : Public Offering
Details : The offering will be used to fund phase 3 trial of VT-001 (atacicept), a fusion protein that blocks both BLyS and a proliferation inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune disea...
Brand Name : VT-001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 06, 2023
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : J.P. Morgan
Deal Size : $115.0 million
Deal Type : Public Offering
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : J.P. Morgan
Deal Size : $100.0 million
Deal Type : Public Offering
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
Details : The offering will be used to fund phase 3 trial of VT-001 (atacicept), a fusion protein that blocks both BLyS and a proliferation inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune disea...
Brand Name : VT-001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 01, 2023
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : J.P. Morgan
Deal Size : $100.0 million
Deal Type : Public Offering
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TACI-IG (atacicept) is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor that binds to the cytokines B lymphocyte stimulator (BlyS) and a prolifer...
Brand Name : TACI-IG
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 30, 2023
Lead Product(s) : Atacicept
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?